Pfizer targets PhIII with pioneering meningitis B vax

Pharma giant Pfizer ($PFE) is making progress in the Phase II trial of a vaccine for meningitis serogroup B, for which there are no such preventive treatments available. This week the New York-based drugmaker's trial got some ink from media near some of the study sites in the Midwest. "This is an important type of (meningitis), and therefore a vaccine is absolutely required," said Emilio Emini, Pfizer's chief scientific officer for vaccine research, as quoted by The Detroit News. The company hopes to launch a Phase III study of the vaccine by the end of the year. Article

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.